HCPLive Network

Hyponatremia Produces Poor Outcomes in Acute-on-Chronic Liver Failure

Drawing upon data from a large European study, Andrés Cárdenas, MD, reported an association between hyponatremia and acute-on-chronic liver failure (ACLF) during a poster session at the 2013 annual meeting of the American Association for the Study of Liver Diseases held November 1-5, 2013, in Washington, DC.
 
Cirrhosis patients who experience ACLF may face poor short-term survival. The condition is characterized by a systemic inflammatory response, with acute decompensation and organ failure.
 
For their poster, Cárdenas and colleagues from the Institute of Digestive Diseases and Metabolism at the Hospital Clinic and University of Barcelona examined data from the CLIF Acute-on-Chronic Liver Failure in Cirrhosis Study (CANONIC) to determine whether hyponatremia has prognostic value in cirrhotic patients with and without ACLF.
 
The CLIF CANONIC database included the health records of 1,341 consecutive patients at 29 different European centers who presented with acute decompensation of cirrhosis of the liver.
 
Of the 517 patients with acute compensation of cirrhosis available for the study’s 28-day follow-up period, 217 (42.0%) had ACLF at enrollment, while 300 (58.0%) were free of ACLF when they enrolled. Of the group with ACLF, 48 (22.1%) had hyponatremia, which was defined as serum sodium <130meq/L. No hyponatremia was seen in 179 (78.9%) of the ACLF patients.


Further Reading
Investigating the association between hyponatremia and cognition in patients with cirrhosis, Jasmohan Bajaj, MD, and colleagues from Virginia Commonwealth University presented results showing reduced brain edema, better quality of life (QOL), and less caregiver burden with the use of the aquaretic tolvaptan.
High medication adherence and sustained viral response (SVR) has been reported in hepatitis C (HCV) patients taking an interferon-free, short-duration, oral regimen of ribavirin (RBV) combined with 3 direct-acting antivirals (DAAs) that are currently in phase 2b/3 clinical trials.
Emerging data from a clinical trial on triple direct-acting antiviral (DAA) therapy plus ribavirin (RBV) in hepatitis C (HCV) genotype 1 (GT1) patients shows that the low rate of relapse during and after treatment leads to high concordance rates between measurements of sustained viral response (SVR) at 4, 12, and 24 weeks post-treatment.
More Reading
$related2$
$AD300x250BB$